Adamis Pharmaceuticals Corporation is a publicly traded OTC: ADMP biopharmaceutical company combining specialty pharmaceuticals and biotechnology products to create a variety of treatment options in the areas of oncology cancer , immunology, infectious diseases viruses , as well as allergic and respiratory conditions. Adamis is built on a business model that entails licensing innovative programs from companies or institutions and then advancing these initiatives through clinical development, regulatory approvals, and marketing. In order to efficiently accomplish its objectives, the Company operates through two subsidiaries Adamis Laboratories specialty pharmaceuticals and Adamis Therapeutics biotechnology . This structure permits each division to complement one other by providing a combination of pharmaceutical revenue and biotechnology blockbuster potential. The specialty pharmaceutical division will provide revenue to support the development of the Company s therapeutic products.